Living Cell Technologies awaits decision by NZ health minister on local trial

Living Cell Technologies demonstrates porcine insulin uptake after 11 months

Two local scientists are off to the BIO convention in June after winning the Advance BioBusiness award.

Early results from a 78-patient safety trial are promising for Prana's Alzheimer's compound.

As it begins Phase IIa clinical trials, Mesoblast is riding high: its share price is climbing, its market capitalisation is booming and all that promise seems to be coming good.

Share offer to raise funds for Alzheimer's trial.

Combination therapy trial for refractory hep C begins.

Australian biotech Living Cell Technologies (LCT) has been given the green light to start a xenotransplantation trial in diabetic patients in Russia.

Prana Biotechnology has raised $7.8 million in cash to add to its fund for a Phase IIa trial in human patients of its PBT2 compound for Alzheimer's disease.

Melbourne-based Prana Biotechnology has announced that it has received regulatory approval from Sweden's Medical Products Agency (MPA) to start a Phase IIa clinical trial of its proprietary lead compound, PBT2, in patients with early Alzheimer's disease.

The value of the Australian life science sector declined 3.5 per cent during the fourth quarter, ending 30 June 2006, according to the latest BioForum report from PricewaterhouseCoopers (PwC).